Adds details on vaccine in paragraph 2, details on disease in paragraphs 3 & 4
Feb 28 (Reuters) - Britain's health regulator said on Friday it has approved Moderna's MRNA.O vaccine for respiratory syncytial virus in adults 60 years and older.
The shot, branded as mRESVIA, is for the prevention of lower respiratory tract disease in older adults, the Medicines and Healthcare products Regulatory Agency (MHRA) said.
RSV is a common virus that spreads very easily and causes infections that can be mild, with cold-like symptoms, but can also cause more serious problems, such as lung infections and pneumonia.
Older adults are at risk of more serious complications that could lead to hospital admission and even death.
GSK's GSK.L vaccine Arexvy and Pfizer's <PFE.N> shot Abrysvo are approved for use in individuals over the age of 60 in the UK.
(Reporting by Sriparna Roy in Bengaluru; Editing by Shilpi Majumdar and Shailesh Kuber)
((Sriparna.Roy@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。